Scholar Rock
Yahoo Finance • 10 months ago
Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK)
Edward Myles, COO & CFO of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 6,634 shares of the company on January 16, 2024, according to a recent SEC filing. The transaction was executed at an average price of $15.93 per share, resulting in... Full story
Yahoo Finance • 2 years ago
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023, and 36-month extension data from Phase 2 TOPAZ trial expected in mid-2023 - Phase 1 DRAGON trial of SRK-181 continues to advance with b... Full story
Yahoo Finance • 2 years ago
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indicate the potential for sustained improvement in quality-of-life measures for patients wit... Full story
Yahoo Finance • 2 years ago
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
CAMBRIDGE, Mass., July 15, 2022--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today... Full story
